98977-34-5 1-N-Boc-4-氧代-3-哌啶羧酸乙酯

中文名称: 1-N-Boc-4-氧代-3-哌啶羧酸乙酯
英文名称: 1-tert-Butyl 3-ethyl 4-oxopiperidine-1,3-dicarboxylate
CAS号

词条详情加载中…

名称和标识

中文名: 1-N-Boc-4-氧代-3-哌啶羧酸乙酯
英文名: 1-tert-Butyl 3-ethyl 4-oxopiperidine-1,3-dicarboxylate
CAS号: 98977-34-5
分子式: C13H21NO5
分子量: 271.31
中文别名: 1-Boc-4-氧-3-哌啶羧酸乙酯; 1-叔丁氧羰基-4-氧-3-哌啶羧酸乙酯; N-BOC-4-哌啶酮-3-甲酸乙酯; N-BOC-4-氧代-3-哌啶甲酸乙酯; 1-N-叔丁氧羰基-4-氧代-3-哌啶羧酸乙酯; 1-叔丁氧羰基-3-乙氧基羰基-4-哌啶酮; N-BOC-4-氧代哌啶-3-甲酸乙酯; 1-tert-丁氧羰基-4-氧-3-哌啶羧酸乙酯; 1-Boc-4-氧代-3-哌啶羧酸乙酯; N-BOC-3-乙氧羰基-4-哌啶酮
英文别名: N-Boc-3-Carboethoxy-4-Piperidone; 1-O-tert-butyl 3-O-ethyl 4-oxopiperidine-1,3-dicarboxylate; Ethyl 1-tert-Butoxycarbonyl-4-oxo-3-piperidinecarboxylate; 1,3-Piperidinedicarboxylic acid, 4-oxo-, 1-(1,1-dimethylethyl) 3-ethyl ester; 1-(1,1-Dimethylethyl) 3-ethyl 4-oxopiperidine-1,3-dicarboxylate; 3-Ethyl 1-(2-methyl-2-propanyl) 4-oxo-1,3-piperidinedicarboxylate; 1-N-Boc-4-Oxo-3-Piperidinecarboxylic Acid Ethyl Ester

物化属性

BBB通透性: No
Brenk警报数: 2.0
CYP1A2抑制剂: No
CYP2C19抑制剂: No
CYP2C9抑制剂: No
CYP2D6抑制剂

安全信息

安全说明

运输信息：常温运输。危险描述：非危险化学品。

生产及用途

用途与制备

化学合成

路线1：

步骤: 将1-苄基-3-乙氧基-4-哌啶酮盐酸盐（IA）的乙醇溶液和Pd/C在1臂氢化，反应完成后加入三乙胺和（Boc）₂O，搅拌后过滤除去催化剂，浓缩萃取干燥得到产物IB。
条件: Stage #1: With hydrogen In ethanol at 20℃; for 15 h; Stage #2: With triethylamine In ethanol at 20℃; for 16 h;
收率: 100%
参考文献: [1] Patent: WO2008/130584, 2008, A1. Location in patent: Page/Page column 131; 135 [2] Organic Process Research and Development, 2011, vol. 15, # 5, p. 1138 - 1148 [3] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 13, p. 3970 - 3975 [4] Patent: WO2011/103091, 2011, A1. Location in patent: Page/Page column 93

路线2：

步骤: 向0-氧代哌啶-3-羧酸乙酯盐酸盐的1M Na₂CO₃和CH₂Cl₂双相混合物中加入Boc₂O，搅拌后用2M HCl处理，萃取干燥浓缩得到产物。
条件: With sodium carbonate In dichloromethane; water at 20℃; for 6.50 h;
收率: 99%
参考文献: [1] Bioorganic and Medicinal Chemistry, 2008, vol. 16, # 2, p. 822 - 829 [2] Journal of Medicinal Chemistry, 2013, vol. 56, # 4, p. 1693 - 1703 [3] Bioorganic and Medicinal Chemistry, 2007, vol. 15, # 16, p. 5590 - 5603 [4] Patent: WO2008/5511, 2008, A2. Location in patent: Page/Page column 101 [5] Patent: WO2008/31772, 2008, A1. Location in patent: Page/Page column 129-130 [6] Tetrahedron, 1991, vol. 50, # 2, p. 515 - 528 [7] Patent: WO2010/138430, 2010, A1. Location in patent: Page/Page column 36 [8] Patent: WO2011/22213, 2011, A1. Location in patent: Page/Page column 32-33 [9] Tetrahedron: Asymmetry, 1993, vol. 4, # 4, p. 625 - 628 [10] Tetrahedron Asymmetry, 2004, vol. 15, # 20, p. 3281 - 3287 [11] Journal of the Chemical Society - Perkin Transactions 1, 1998, # 22, p. 3673 - 3683 [12] Organic letters, 2000, vol. 2, # 25, p. 4037 - 4040 [13] Patent: US6448263, 2002, B1 [14] Patent: US5756508, 1998, A [15] Patent: WO2008/58387, 2008, A1. Location in patent: Page/Page column 13 [16] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 23, p. 5478 - 5483 [17] Patent: US2015/368242, 2015, A1. Location in patent: Page/Page column 15; 16 [18] Patent: WO2008/141462, 2008, A1. Location in patent: Page/Page column 30 [19] Patent: WO2009/87, 2008, A1. Location in patent: Page/Page column 38; 32 [20] Patent: WO2009/109608, 2009, A1. Location in patent: Page/Page column 48-49